BCR-ABL1 splice variants and uses thereof
AssigneeQuest Diagnostics Investments Incorporated
InventorWanlong Ma
Life of this patent
Estimating the term…
Abstract
The present invention is based on BCR-ABL1 splice variants which result from insertion and/or truncation of the bcr-abl1 transcript and the finding that these variants provide resistance to kinase domain inhibitors such as imatinib, nilotinib and dasatinib.
Claims13
A method of detecting the presence of a nucleic acid encoding a 243-INS bcr-abl splice variant in a sample comprising bcr-abl nucleic acids, comprising contacting the sample with a labeled nucleic acid probe that hybridizes to the 5′ junction site or the 3′ junction site of the intron 6 insertion of the 243-INS bcr-abl splice variant and detecting the hybridized labeled nucleic acid probe to detect the bcr-abl splice variant.
Dependencies are inferred from the claim text.